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Summary 
Four human B cell lines established by Epstein-Barr viral transformation of B cells from a patient 
with a clinical diagnosis of Alzheimer's disease (AD) were found to secrete antibodies that react 
with plaques and cerebrovascular blood vessels in AD brain in a staining profile characteristic 
of B-amyloid protein (fl-AP) in AD brain.  Two of these antibodies were shown to be reactive 
with a rare plaque in a normal brain.  In these studies, immunofluorescence and avidin-biotin 
complex immunoperoxidase methodology were used to determine antibody reaction, and thioflavine 
S was used to double label amyloid and neurofibrillary tangles. The four antibodies also reacted 
with neurons  in normal and AD brain.  Absorption studies, dot immunoblots, and enzyme- 
linked immunosorbent assays with/~-amyloid peptides 1-28 (~/-A1-2s) and 1-40 (fl-Ai-40) indicate 
the major determinant of the reactive epitope is located in the region of amino acids 1-28 of 
~-AP. However, inhibition  studies demonstrate a significant contribution to the antigenic de- 
terminant by the 29-40  region of the B'A1-40.  These  antibodies  represent  the first  human 
autoantibodies  against ~/:AP. The pathological  significance of these autoantibodies is discussed. 
I 
n Alzheimer's Disease (AD), the neuropathological  hall- 
marks include  unusually high numbers of plaques and 
neurofibrillary tangles (NFT) in the hippocampus, neocortex, 
and amygdala (reviewed in references 1 and 2). One compo- 
nent of the NFT is r protein,  a microtubule-associated pro- 
tein (MAP). The plaques contain fl-amyloid protein (~/-AP), 
a fragment of 42-43 amino acids of the fl-amyloid precursor 
protein (APP). There is significant neuronal loss in specific 
areas of the AD brain. Marked astrocytosis also accompanies 
these changes. Recent genetic studies have shown a single 
amino acid substitution in the transmembrane portion of the 
APP in some familial AD (reviewed in reference 1). Both 
genetic and environmental factors are thought to be impor- 
tant. Our studies and those of others suggest that there may 
be circulating antibodies that are specific for antigens in AD 
brain (reviewed in reference 3). 
Our approach to study AD has been to immortalize B cells 
from patients with AD, other neurodegenerative disorders, 
strokes, and age-matched controls by EBV. This approach 
was undertaken by us to circumvent the difficulties  in defining 
the specificities of serum autoantibodies  unique for AD pa- 
tients.  These difficulties include the low concentrations  of 
relevant antibodies and the presence of other autoantibodies 
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to cellular constituents in aged individuals.  Our previous 
studies have identified unique anti-NFT and antineural anti- 
bodies (4-6). 
We have derived multiple B cell lines from blood obtained 
on three separate occasions from a patient with a clinical di- 
agnosis  of AD.  There was  considerable  variation  in  the 
numbers of B cell lines established from each sample. It is 
of interest  to note that in one of the three blood samples, 
four cell lines were found to secrete antibodies reactive with 
plaques and blood vessels in AD brain in a staining profile 
characteristic of B-AP. The characterization of these four an- 
tibodies  is described in this report. 
Materials and Methods 
Derivation of EBV-transformed  B Cell Lines.  EBV-transformed B 
cell lines were derived from a patient with a clinical  diagnosis of 
AD at 69,  73,  and 74 yr of age according to Gaskin et a].  (4). 
On these three separate occasions, 522, 684, and 190 cell lines were 
established,  respectively.  Three of the four cell lines  used in this 
paper contained only one class of light chains, suggesting they are 
monoclonal or oligodonal. One of these has been cloned by forming 
hybridomas with K6H6/B5 obtained from American Type Cul- 
ture Collection (Rockville, MD) according to Carroll et al.  (7). 
The fourth cell line,  MRE310,  contained K and X chains.  It was 
also fused with K6H6/B5. Two positive hybrids were cloned twice 
by the limiting dilution method. The cloned hybridomas secreted 
only Ic chain. 
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activity on AD brain by immunofluorescence was done on cryostat 
sections from AD temporal cortex (middle temporal gyrus) rich 
in plaques and NFT as previously described (4, 6). Antibodies posi- 
tive for plaques  were also tested using the ABC immunoperoxi- 
dase method previously described  (4).  Positive plaque antibodies 
were tested for reaction on temporal cortex of five AD (57,  69, 
73,  80,  and 87 yr old) and four normals (50,  61, 65,  and 67 yr 
old). To determine possible antibody labeling of NFT, plaque neu- 
rites, and neuritic processes, double labeling was carried out as pre- 
viously described (6), using the human antibodies and rhodamine- 
conjugated anti-human  antibodies as described  above and using 
anti-r-2 (Sigma Chemical Co., St. Louis, MO) at a 1:50 dilution 
and ftuorescein-conjugated goat anti-mouse IgG. 
Inhibition Studies.  Equal  volumes  of peptides  (initially  400 
ng//~l  in  0.15  M  NaC1)  or  0.15  M  NaC1  only were added  to 
diluted supernatants.  After 2 h  at room temperature, they were 
analyzed on tissue as described above. Peptides tested included the 
following ~8-amyloid  peptides:  ~-Al-z8.glu-11  (Sigma Chemical Co.); 
3-At-28.gl,-n (Sigma  Chemical  Co.,  and  Bachem Inc.,  Torrance, 
CA);  3-A1-40.gLu-n (Bachem Inc.);  3-Al-16~sln-ll (Sigma  Chemical 
Co.), and B-A12-2s (Sigma Chemical Co.). Two human IgM anti- 
bodies (CAN15, which stains NFT, plaque neurites, and neuritic 
processes; and KKN351, which stains astrocytes  [6]) were used as 
controls. 
Dot Immunoassay.  Aliquots,  10 #1 of 1-4/~g peptide or BSA 
in 0.15 M NaC1 or 0.15 M NaC1 only, were dried onto nitrocellu- 
lose paper.  Antibodies were serially diluted and allowed  to react 
for 2 h at room temperature. Antibodies were also tested for reac- 
tivity to the cytoskeletal proteins bovine muscle myosin, porcine 
muscle actin, human epidermal keratin (all from Sigma Chemical 
Co.); bovine glial fibrillary  acidic protein (ICN Biomedical  Inc., 
Costa Mesa,  CA);  and porcine brain tubulin and MAPs purified 
as described  (8). Experiments were done with 10/~1 of 20 ~g/ml, 
200 #g/ml, and 1 mg/ml of cytoskeletal  proteins in the dot blot. 
Human antibodies positive for cytoskeletal  proteins were used as 
controls. Blots were scanned with a multimedia densitometer (Gil- 
ford Systems,  Oberlin,  OH).  Peak heights and areas were calcu- 
lated with the laboratory computing integrator (LCI-100; Perkin- 
Elmer Corp., Norwalk, CT). Antibodies were considered negative 
if <5%  of the value of the positive  control. MRE1  was used as 
a negative control. 
ELISA.  ELISAs with ~-A1-28.gln-11  or/~-A1-4o and cytoskeletal 
proteins were done as previously described  (6).  50/zl of peptides 
(5/zg/ml) or 100 #1 of cytoskeletal proteins at 2-5 #g/ml was used. 
Peptides used in the inhibitive ELISA were incubated with the an- 
tibodies for 1.5 h at room temperature. As an added control, two 
antibodies with other reactivities (MRE1 and CAN15) were treated 
similarly. These antibodies  failed to yield readings  above the back- 
ground. 
Results 
Antibodies  Reactive with fl-Amfloid Peptide-positive Plaques 
and Blood Vessels in AD Brain.  Four antibodies from EBV- 
transformed B cell lines established from a single blood sample 
from a 73-yr-old female AD patient were found to react with 
AD temporal cortex in a profile characteristic of B-AP. De- 
spite multiple cell lines being established on two other occa- 
sions,  this  pattern  of reactivity was  not  noted.  These four 
cell lines were MRE148, MRE267, MRE293, and MRE310. 
They have been found  to  secrete monoclonal  IgM. 
By either immunofluorescence or the avidin-biotin com- 
plex (ABC) immunoperoxidase method, the four antibodies 
stained  plaques,  neurons,  and  blood  vessels  with  amyloid 
deposits in five cryopreserved AD brains. These five AD brains 
were selected because of the presence of different amounts 
of primitive plaques, classical plaques, compact plaques, diffuse 
deposits, and stellate deposits. In the case of immunofluores- 
cence, thioflavine S was used to label B-AP in the plaques 
and blood vessels. In every section, there was complete overlap 
between immunofluorescence (red) and green fluorescence due 
to thioflavine S staining.  The results of a representative ex- 
periment are shown in Fig.  1. In this experiment, MRE148 
Figure 1.  (A) Plaque  labeling  by 
antibody MRE148 on AD brain as 
detected by rhodamine-conjugated 
goat anti-human  Ig fraction (red 
fluorescence).  (B) Antibody MRE- 
148 reactivity with deposits in a 
cerebrovascular  blood vessel in AD 
brain. (C) The same section as in 
A counterstained with thioflavine 
S, which emits green fluorescence 
(x 290). (/3)  The same  section  of the 
blood  vessel in B  showing thio- 
flavine S positive deposits (x 145). 
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ing  antibody MRE310 reaction 
with plaques and neurons in AD 
brain temporal cortex  (A) and blood 
vessels and plaques in AD frontal 
cortex (C). B and D are the adja- 
cent sections of A and C, respec- 
tively, and were  reacted  with MRE- 
310, which had been absorbed  with 
3-A1-2s,gt,-11  at 100 ng//xl. B and D 
demonstrate the loss  of MRE310  an- 
tibody reactivity after absorption. 
(A and B)  x80; (C and D)  x115. 
was shown to  stain  three plaques and a blood vessel  with 
amyloid deposits by immunofluorescence (Fig.  1, A  and B), 
which were identified by thioflavine S staining (Fig. 1, C and 
D). It is evident that there is complete overlap between both 
red and green fuorescence.  All other  human  antibodies in 
our collection that are reactive with cellular constituents do 
not stain in this manner (see references 4 and 6). In addition, 
these antibodies were not reactive with  NFT,  plaque neu- 
rites, and neuritic processes that were identified with an anti- 
r-2 mAb by double labeling. The staining of neurons in AD 
brains by these antibodies was seen by both immunofluores- 
cence and the ABC method. The latter method does not have 
autofluorescence due to lipofuscin and allows better photog- 
raphy.  Typical neuronal  staining  is  shown in  Fig.  2. 
Neuronal staining with the four antibodies was also seen 
on all four normal brains that were studied. The blood vessels 
in these normal brains were nonreactive with either the anti- 
bodies or thioflavine S, indicative of the absence of 3-AP. The 
staining of normal brain by these antibodies deserves further 
comment. Although the control brains were selected to con- 
tain few NFT and plaques, one of the normal brains (65 yr) 
contained an area with neurofibrillary tangles and a plaque 
confirmed by thiofavine S. Multiple sections were cut through 
this plaque.  This plaque was reactive with the three antibodies, 
MRE148,  MRE267,  and  MRE310,  that  were tested. 
Identification of fl-Ai-4o  as the Reactive Antigen.  To dem- 
onstrate that the antibodies were against ~-AP, the four anti- 
bodies were incubated with several peptides (200-250 ng//zl 
serially diluted twofold) before reaction on AD brain.  Incu- 
bation with peptide ~-A1-40 at 25 ng//~l resulted in complete 
loss of antibody reactivity whereas peptides 3-A1-2s.glu-ll or 
3-A1-2s.gln-ll required  100-200 ng//xl  (depending  on which 
antibody) for complete inhibition.  These experiments were 
done by both immunofluorescence  and  the ABC method. 
The latter method provided unambiguous results, as shown 
in  Fig.  2,  which  demonstrates  an  absorption  study with 
MRE310 and/~-Al-zS,gln-11. The  staining  of plaques,  blood 
vessels, and neurons in AD brain by MRE310 is completely 
abolished by/~-A1-2s,g~-11 at 100 ng/#l.  3-A1-40 was also used 
for similar experiments. 25 ng//zl was sufficient for complete 
absorption. Similar results were obtained with the other three 
antibodies.  In  general,  it  required  four-  to  eightfold  more 
when  peptide  B-A1-2s was  used  to  completely  block  the 
staining. The degree of inhibition was generally proportional 
to the amount  of the peptide used.  No inhibition  of anti- 
body reactions  on  AD brain  was found with  B-A1-16 and 
~-A12-2s even at  750 ng//zl. 
Reactivity  with  flAP  Peptides in  the  Dot  Blot  and  in  the 
ELISA.  The  reactivities of the four plaque-positive  anti- 
bodies to/~-A1-4o,  ~-A1-2s,glu-11, and/~-A1-2S,glu-ll were also 
demonstrated by immunoblotting.  A representative of three 
experiments is shown in Fig. 3. All four antibodies were reac- 
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of  synthetic  ~-A1-2S,gln-11, 
B-APl-28,gh-n, ~-A12-2s, B-Al-16, 
and B-A1-40  with selected MILE 
antibodies. The antigen is indi- 
cated on the left and the dilution 
of antibody on the right. Lanes 
A-E  designate  the  antibodies 
used: lane A, MRE293;  lane B, 
MRE1; lane C, MRE148; lane D, 
MILE267; and lane E, MRE310. 
MRE1  is an IgM antibody that 
shows no reaction on brain. The 
other four antibodies react with 
plaques and blood vessels in AD 
brain and neurons in normal and 
AD brain. 
tive  to  B-At-4o in  the  dot  blot.  Three  of the antibodies, 
MRE148, MRE267, and MRE310, were more reactive with 
B-A1-2s.st,-11  whereas  MRE293  was  more  reactive  with 
/5-At-2s.#-,.  These results suggest that MRE293 recognizes 
a somewhat different epitope than the other three antibod- 
ies. The four antibodies  were nonreactive to B-A12-2s and 
~-A1-16. 
By densitometric scanning, MRE148 was most reactive to 
~-A1-4o. The blotting intensity of MRE148 to ~-At-4o is ar- 
bitrarily set as 1 and used as a reference. MRE310 was next 
in this reactivity with 0.80, followed by MRE267 with 0.71, 
and then by MRE293 with 0.30.  Similarly,  scanning of the 
reactivities of antibodies at  a 1:25  dilution  to  ~-A1-28,glu-11 
resulted in  MRE148  (1.0)  >  MRE310  (0.59)  >  MRE267 
(0.47)  >  MRE293  (0.15),  whereas antibody reactivities to 
B-At-2s,#-11  were  MRE148  (0.70)  >  MRE267  (0.39)  > 
MRE 310  (0.36)  >  MRE293  (0.27).  Scanning of the dots 
against/~-Alv2s and B-A1-16 yielded negative results.  MRE1, 
which is an IgM with an unknown antigenic reactivity and 
without antibrain activity, was used as a negative control in 
these experiments. 
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Figure 4.  ELISA  to measure the ability of B-A1-4o (O), ~-A1-28,glu-ll 
(~),  B'A1-2S.gln-ll  (O),  ~-A1-16  (r]),  and B'A12-zs (V)  to  inhibit the 
binding of MRE310 to jS-Al-40.  The inhibitory potencies of both 1-28 
peptides were similar and thus a single curve has been drawn through these 
points. 
The 3-amyloid antibodies were negative on dot blots using 
the cytoskeletal proteins myosin, actin, keratin, glial fibril- 
lary acidic protein,  tubulin,  and MAPs as antigens at con- 
centrations up to 10/*g/dot.  They were also negative in an 
ELISA using the same panel of cytoskeletal proteins. 
The  four anti-~-amyloid antibodies  were reactive with 
~-A1-2s and B-A1-4o in the ELISA.  Inhibition  studies were 
also  done.  In  a  typical  experiment,  as  shown  in  Fig.  4, 
MRE310  binding  to  /~-A1-4o was  blocked  with  various 
~-amyloid peptides.  The inhibitory potencies of/~-A1-2S,gl,ql 
and ~-A1-2S.g~-u were similar. Thus, a single curve was fitted 
through these points. With B-Alqo, 0.5 #g yielded 50% in- 
hibition. With ~-At-2s,  7 #g was needed. Both/~-At-t6 and 
/~-At2-2s at 24/~g did not significantly inhibit in the ELISA. 
Similar results were found with the other three antibodies 
in this ELISA system. These data are in agreement with the 
inhibition results obtained in immunohistochemical studies 
described in the previous section. The results from the two 
inhibition assays document that there is a significant contri- 
bution to the reactive epitope by the sequence 29-40 in the 
#-At-40. 
Discussion 
In the present study, four human mAbs were identified 
to be reactive with ~-AP in AD. This was supported by im- 
munohistochemical studies and ELISAs with ~-amyloid pep- 
tides as substrates.  These antibodies stained all plaques and 
neurons in both normal and AD brains. This reactivity differs 
from the reactivity of antibody 161  described by Simpson 
et al. (9), which also reacts with plaques and neurons. How- 
ever, Ab 161 did not react with the birefringent material in 
the plaques when Congo red was used to identify ~-amyloid 
in the plaque and the antibody also stained the nuclei of the 
neurons. Thus, these four antibodies represent the first human 
autoantibodies against B-AP. 
The nature of the reactive epitope was explored. The reac- 
tive epitope appears  to reside in the region of amino acids 
1-28 of the/3-At-4o.  Further analysis suggests that the reac- 
tive epitope is conformational in that there is a significant 
contribution to the antigenic determinant by the region 29-40. 
In comparison with/8-A1-40,  four- to eightfold greater con- 
centrations of 3-A1-2s were required in immunohistochem- 
ical studies to block the staining of amyloid plaques.  It ap- 
pears that the conformational nature of the reactive epitope 
is conserved in the amyloid plaques in situ. This epitope also 
differs from those recognized by xenogeneic antibodies raised 
against 3-At-2s (10-12).  Thus, these antibodies recognize a 
unique epitope on the 3-AP and their reactions represent an 
added example of uniqueness of epitopes reactive with au- 
toantigens. 
>6,000 EBV-transformed/~ cell lines from both normals 
(1,705 from six individuals), patients with AD (2,834 from 
six individuals), and other diseases (1,825 from six individ- 
uals) have been screened for their reactivity against AD brain 
sections. Only four were found to react with the ~-AP. These 
four lines were derived from the blood of a single bleed from 
a single individual with AD.  It appears  that these anti-/3- 
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The fact that these cell lines were established from only one 
of the three bleeds underscores the importance of repeated 
studies in a single individual when peripheral blood is used 
for the generation of human cell lines or hybridomas secreting 
specific  antibodies  of interest. 
The  role of 3-AP in  the  pathogenesis  of AD  has  been 
reviewed (1,  2).  It appears that  an excessive  production  of 
APP and the generation  and accumulation  of B-AP in the 
brain are characteristic of AD and related disorders. Recently 
3-AP was reported to be found in various tissues and in cir- 
culation (13, 14). The mechanism for its selective accumula- 
tion in the AD brain remains to be elucidated. The presence 
of circulating/3-AP may preclude the detection of circulating 
anti-B-amyloid antibodies and provides an explanation  for 
our inability to detect these antibodies in the patients'  sera 
(n  =  10). Whether  these antibodies can be detected in the 
cerebrospinal fluid of AD patients remains to be determined. 
The  availability of these cell lines  allows us to  determine 
whether there are extensive mutations in the V  regions by 
sequencing the mRNA encoding for these regions. The ex- 
istence of extensive mutations in these regions would indi- 
cate the process is antigen driven. The presence of aggregated 
3-AP may be relevant to this process in that aggregated pro- 
teins have been known  to break humoral  tolerance. 
The presence of complement components in plaques in AD 
brain has been well documented (reviewed in references 15-18). 
The presence of Clq in plaques is indicative of complement 
activation via the classical  pathway. The detection of Ig in 
the plaques has been reported.  The Ig deposits do not fre- 
quently colocalize with Clq deposits. Recently, Rogers et 
al. (17) have obtained evidence that ~-AP binds Clq and acti- 
vates complement in an Ig-independent  manner.  However, 
these observations do not exclude the possibility that anti-B- 
amyloid antibodies may participate in complement fixation 
in vivo and contribute to the pathogenesis of AD.  In this 
regard, the bound Ig may be solubilized as the consequence 
of complement fixation.  Relevant to this discussion is the 
recent observation by Levine et al. (19) that in a murine model 
in which oe virus is produced in brains of adult mice with 
severe combined immunodeficiency with little central nervous 
system (CNS) pathology, intraperitoneal injections of specific 
antibodies clear oe virus infection from brain neurons. It has 
been difficult to demonstrate the presence of the injected an- 
tibodies in the brain.  Thus,  our understanding  of immune 
clearance in the CNS is incomplete and the extrapolation of 
mechanisms in other organ systems to the CNS should be 
carried out with caution. Therefore, a pathogenetic role of 
anti-B-amyloid antibodies cannot be dismissed at the present. 
Because of the rare incidence of these antibody-secreting lines 
and since all four lines were generated from a single patient, 
one cannot conclude that this antibody is disease related.  How- 
ever, it is now feasible to generate antiidiotypic antibodies 
to these anti-3-amyloid antibodies.  The staining of Ig deposits 
in the AD brain by these antiidiotypic antibodies would add 
support  to a pathogenetic  role of these antibodies. 
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